Related Experiment Video
Updated: Feb 7, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Progress in the treatment of solid tumors with apatinib: a systematic review
Deze Zhao1, Helei Hou1, Xiaochun Zhang1
1Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266003, China, zhangxiaochun9670@126.com.
Abstract:
With the investigation of molecular targets, many agents, such as trastuzumab and ramucirumab, have attained a positive outcome in oncotherapy. Vascular endothelial growth factor (VEGF) is considered a potent factor in angiogenesis and plays an important role in the growth of tumors. Moreover, both VEGF and its receptor are usually excessively expressed in solid tumors and could be hopeful targets for the treatment of neoplasms. Apatinib (YN968D1) is an oral small-molecule tyrosine kinase inhibitor of VEGFR-2. By inhibiting several signaling transduction pathways, it restrains angiogenesis and subsequently controls tumorigenesis. According to current studies, apatinib shows promising application in various solid tumors as a post-second- and post-third-line treatment. It could significantly improve the median overall survival and progression-free survival of patients with tolerated adverse reactions. This paper aims to summarize the recent research on apatinib including the mechanism, pharmacokinetics, trials, adverse reactions, and prospect as a treatment.
Insights
Apatinib, an oral VEGFR-2 inhibitor, shows promise in treating solid tumors by blocking angiogenesis. It improves survival outcomes for patients with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- Vascular Endothelial Growth Factor (VEGF) drives tumor angiogenesis and growth.
- VEGF and its receptor are overexpressed in many solid tumors, making them therapeutic targets.
- Targeting molecular pathways has led to successful oncotherapy agents.
Purpose of the Study:
- To summarize recent research on apatinib, an oral small-molecule tyrosine kinase inhibitor of VEGFR-2.
- To review apatinib's mechanism of action, pharmacokinetics, clinical trials, and adverse reactions.
- To discuss the therapeutic prospects of apatinib in cancer treatment.
Main Methods:
- Review of current studies on apatinib.
- Analysis of apatinib's mechanism in inhibiting angiogenesis and tumorigenesis.
- Evaluation of clinical trial data regarding efficacy and safety.
Main Results:
- Apatinib inhibits VEGFR-2, restraining angiogenesis and tumor growth.
- It demonstrates promising efficacy as a post-second- and post-third-line treatment for various solid tumors.
- Apatinib significantly improves overall survival and progression-free survival with tolerable adverse reactions.
Conclusions:
- Apatinib is a potential therapeutic agent for solid tumors by targeting VEGF signaling.
- Its ability to improve survival outcomes warrants further investigation and clinical application.
- Further research into its mechanism, pharmacokinetics, and long-term effects is ongoing.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...

